CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor
Background and Aims: Emicizumab has changed the prophylaxis paradigm of hemophilia A (HA). Despite its fixed-dose, measuring emicizumab plasma concentration ([E]p) may be occasionally useful and the global hemostatic response could be monitored through Thrombin Generation Assay (TGA). Our aim is de...
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
PAGEPress Publications
2025-08-01
|
| Series: | Bleeding, Thrombosis and Vascular Biology |
| Subjects: | |
| Online Access: | https://www.btvb.org/btvb/article/view/241 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CO36 | Inhibitor titer at diagnosis and clinical course in acquired hemophilia A: a single-center experience
Published: (2025-08-01) -
CO39 | Artificial intelligence in hemophilia management: challenging the need for experts
Published: (2025-08-01) -
CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal
Published: (2025-08-01) -
CO38 | Management of pregnancy, delivery, and postpartum in Italian carriers and women with hemophilia A and B
Published: (2025-08-01) -
CO30 | Joint prosthetic surgery in patients with hemophilia A: clinical-functional outcomes and quality of life
Published: (2025-08-01)